类风湿关节炎药物效应非劣效性试验的评估
该研究探讨了在类风湿关节炎(RA)中评估新药的非劣效性(NI)试验的设计考虑,以已批准的肿瘤坏死因子抑制剂(TNFi)作为阳性对照,通过荟萃分析估计TNFi对症状、功能和影像学进展的效应,并提出非劣效性界值。结论认为,设计合理的非劣效性试验可提供令人信服的证据,推荐在未来RA临床试验中考虑非劣效性设计。
要点
- 以TNFi为阳性对照的非劣效性试验可行,症状终点ACR20的绝对差异界值可为12%。
- HAQ-DI评分变化的合理非劣效性界值范围为0.10至0.12。
- 影像学进展的非劣效性界值及可行性取决于所选阳性对照和预期进展变异性。
核心结论
- 在RA中,采用合理非劣效性界值的阳性对照研究可为症状、功能和影像学终点提供有说服力的治疗效应证据。
研究设计与样本
- 本研究聚焦于以已批准TNFi作为潜在阳性对照,并回顾既往安慰剂对照研究,通过荟萃分析估计TNFi效应。
主要发现
- 荟萃分析估计了TNFi对RA症状、身体功能和影像学进展的效应。
- 以ACR20应答为症状终点时,12%绝对差异是可能合适的非劣效性界值之一。
- HAQ-DI评分较基线变化的合理界值范围为0.10至0.12。
关键数值与推荐
- 症状终点ACR20应答的非劣效性界值可为12%绝对差异。
- HAQ-DI评分变化的非劣效性界值范围为0.10至0.12。
- 影像学进展的非劣效性界值取决于所选阳性对照和预期进展变异性。
临床怎么用
- 在RA未来临床试验中可考虑非劣效性设计,以评估新药相对于TNFi的效应。
- 非劣效性试验还可提供可靠的对照安全性数据和临床实践决策相关信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The increased availability of highly effective treatments in rheumatoid arthritis (RA) necessitates a reexamination of study designs evaluating new treatments. We undertook this study to discuss possible specifications and considerations of noninferiority (NI) trials assessing drug effects in RA. METHODS: We focused on the use of approved tumor necrosis factor inhibitors (TNFi) as potential active controls and reviewed previous placebo-controlled studies. We summarized the similarities in baseline characteristics and study design of the historical placebo-controlled studies used. After performing meta-analyses to estimate the effects of TNFi on symptoms, physical function, and radiographic progression in RA, we proposed NI margins and evaluated the feasibility of NI trials in this therapeutic setting. RESULTS: We determined that an NI trial comparing an experimental treatment to a TNFi using the symptomatic end point of the American College of Rheumatology 20% improvement criteria response can feasibly provide evidence of a treatment effect, with a 12% absolute difference as one possible appropriate NI margin. For change from baseline in the Health Assessment Questionnaire disability index score, reasonable margins range from 0.10 to 0.12. In evaluating radiographic progression, an appropriate margin and the corresponding feasibility of the trial are dependent on the selected active control and the expected variability in progression. CONCLUSION: Active-controlled studies in RA with justified NI margins can provide persuasive evidence of treatment effects on symptomatic, functional, and radiographic end points. Such studies can also provide reliable, controlled safety data and relevant information for treatment decisions in clinical practice. Thus, we recommend considering NI designs in future clinical trials in RA.
引用
- Rothwell R, Nikolov NP, Maynard JW, et al. Noninferiority Trials to Evaluate Drug Effects in Rheumatoid Arthritis. Arthritis Rheumatol. 2020. PMID: 32182406. doi:10.1002/art.41257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。